Work

Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps4147

Authors: E. Gabriela Chiorean, Shannon McDonough, Philip Agop Philip, Elizabeth M. Swisher, Michael J. Pishvaian, Katherine Guthrie, Andrew M. Lowy, Howard S. Hochster

Institutions: Fred Hutch Cancer Center, The Barbara Ann Karmanos Cancer Institute, University of Washington, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Moores Cancer Center, Yale Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890782063

Cites:

Cited by: 3

Related to: 10